About CHV

We focus on investment opportunities within the healthcare and life science markets where we can identify value early. At the core of our investment philosophy is a committed and collaborative approach to working with management teams and syndicate partners to build successful companies.

We work actively with founders, providing guidance, support and access to our network. We strongly believe that no two investments are the same and support the most suitable business model for each individual venture, working with management teams to formulate strategies to achieve financial independence. We are comfortable financing companies by ourselves and, if appropriate, working closely with the founders to help build a syndicate of co-investors who bring complementary relationships and share our vision.

We have a 14-year history of continuous dedication to the fast growing MedTech sector and a history of backing successful entrepreneurs transforming healthcare through MedTech innovation.

Investment Strategy

Focus: Within the broader healthcare market, we focus our investments on medical technologies including medical devices, diagnostics, drug delivery, and digital health. We back both first-time and experienced founders, who value our participation as well our capital.


Stage: We are typically the first institutional investor and support companies through early product and clinical development and often through the regulatory process. We make our first investment at the seed through series B stage, based on when the risk of translation from pre-clinical to clinical is at its lowest. We are life cycle investors and continue to support our portfolio companies through to exit.


Capital Efficiency: We invest in companies that are able to demonstrate early and meaningful clinical value with minimum capital invested and preserve the most appropriate exit opportunity.


Therapeutic Indications: While we are agnostic to therapeutic indication, we invest in companies developing products that address large, global markets and where there is significant unmet clinical need. We particularly like therapeutic devices that significantly improve patient outcomes and diagnostics that fundamentally change the course of therapeutic intervention.